The cardiac ryanodine receptor (RyR2) and its role in heart disease

Cardiology in Review

Volumn 13, Issue 3, 2005, Pages 142-146

  Taur, Ying ^a   Frishman, William H ^b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Calcium influx; Excitation contraction coupling; Heart failure; Ryanodine receptor; Sarcoplasmic reticulum

Indexed keywords

2,6 DICHLORO 4 DIMETHYLAMINOAMPHETAMINE; 4 (2 BENZYLBENZOYL) 2,5 DIMETHYL 1H PYRROLE 3 CARBOXYLIC ACID METHYL ESTER; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; 4 CHLORO 3 CRESOL; 4,6 DIBROMO 3 HYDROXYCARBAZOLE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTHRAQUINONE DERIVATIVE; BASTADIN 5; DANTROLENE; DIGOXIN; DOXORUBICIN; ENFLURANE; HALOTHANE; HEPARIN; HEXACHLOROCYCLOHEXANE; ISOFLURANE; LIDOCAINE; LIDOCAINE ETHOBROMIDE; METHYLXANTHINE DERIVATIVE; MILRINONE; NEOMYCIN; PROCAINE; QUINOLIDOMICIN A1; RAPAMYCIN; RUTHENIUM RED; RYANODINE; RYANODINE RECEPTOR; SULMAZOLE; SURAMIN; TACROLIMUS; TETRACAINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BETA ADRENERGIC STIMULATION; CALCIUM TRANSPORT; EXCITATION CONTRACTION COUPLING; GENE EXPRESSION; GENE MUTATION; HEART CONTRACTION; HEART DISEASE; HEART FAILURE; HUMAN; MUSCLE CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; HEART DISEASES; HUMANS; MACROMOLECULAR SUBSTANCES; MUSCLE CELLS; MUTATION; MYOCARDIAL CONTRACTION; RISK ASSESSMENT; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SENSITIVITY AND SPECIFICITY;

EID: 17844363686     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000128709.84812.86     Document Type: Review

References (22)

1. 2+-ATPase and the ryanodine receptor. Eur J Biochem. 2000;267:5274-5279.
2. 2+ from the sarcoplasmic reticulum of skinned cardiac cells. Nature. 1979;281:146-148.
3. Marks AR. Ryanodine receptors, FKBP12, and heart failure. Front Biosci. 2002;7:d970-977.
4. Stern MD. Theory of excitation-contraction coupling in cardiac muscle. Biophys J. 1992;63:497-517.
5. Benitah JP, Kerfant BG, Vassort G, et al. Altered communication between L-type calcium channels and ryanodine receptors in heart failure. Front Biosci. 2002;7:e263-275.
6. 2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev. 1997;49:1-51.
7. Islam S. The ryanodine receptor calcium channel of beta-cells: molecular regulation and physiological significance. Diabetes. 2002;51:1299-1309.
8. Marks AR. Cellular functions of immunophilins. Physiol Rev. 1996;76:631-649.
9. 2+ release channels (ryanodine receptors). Science. 1998;281:818-821.
10. Marx SO, Reeked S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12. 6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365-376.
11. 10a. Yano M, Kobayashi S, Kohno M, et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation. 2003;107:477-484.
12. Marks AR. A guide for the perplexed. Towards an understanding of the molecular basis of heart failure. Circulation. 2003;107:1456-1459.
13. Lehnart SE, Reiken S, Gaburjakova M, et al. Altered ryanodine receptor single channel properties in skeletal muscle during heart failure [Abstract]. Circulation. 2002;106(suppl II):II-23.
14. Wasserstrom JA, Wasserstrom LA, Lokuta AJ, et al. Activation of cardiac ryanodine receptors by the calcium channel agonist FPL 64176. Am J Physiol. 2002;283:H331-338.
15. Marks AR, Priori S, Memmi M, et al. Involvement of the cardiac ryanodine receptor/calcium release channel in the catecholaminergic polymorphic ventricular tachycardia. J Cell Physiol. 2002;190:1-6.
16. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997;30:1512-1520.
17. Franz WM, Muller OJ, Katus HA. Cardiomyopathies: from genetics to the prospect of treatment. Lancet. 2001;358:1627-1637.
18. Danieli GA, Rampazzo A. Genetics of arrhythmogenic right ventricular cardiomyopathy. Curr Opin Cardiol. 2002;17:218-221.
19. Tiso N, Stephan DA, Nava A, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythinagenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet. 2001;10:189-194.
20. Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol. 1999;34:2035-2042.
21. Marks AR. Clinical implications of cardiac ryanodine receptor/calcium release channel mutations linked to sudden cardiac death. Circulation. 2002;106:8-10.
22. Bauce B, Rampazzo A, Basso C, et al. Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death. J Am Coll Cardiol. 2002;40:341-349.